These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

364 related items for PubMed ID: 8087425

  • 41. Lack of transcriptional repression by max homodimers.
    Yin X, Grove L, Prochownik EV.
    Oncogene; 1998 May; 16(20):2629-37. PubMed ID: 9632139
    [Abstract] [Full Text] [Related]

  • 42. Specific c-myc and max regulation in epithelial cells.
    Martel C, Lallemand D, Crémisi C.
    Oncogene; 1995 Jun 01; 10(11):2195-205. PubMed ID: 7784064
    [Abstract] [Full Text] [Related]

  • 43. The Max homodimeric b-HLH-LZ significantly interferes with the specific heterodimerization between the c-Myc and Max b-HLH-LZ in absence of DNA: a quantitative analysis.
    McDuff FO, Naud JF, Montagne M, Sauvé S, Lavigne P.
    J Mol Recognit; 2009 Jun 01; 22(4):261-9. PubMed ID: 19189276
    [Abstract] [Full Text] [Related]

  • 44. c-Myc creates an activation loop by transcriptionally repressing its own functional inhibitor, hMad4, in young fibroblasts, a loop lost in replicatively senescent fibroblasts.
    Marcotte R, Chen JM, Huard S, Wang E.
    J Cell Biochem; 2005 Dec 01; 96(5):1071-85. PubMed ID: 16167342
    [Abstract] [Full Text] [Related]

  • 45. Phosphorylation regulates Myc expression via prolonged activation of the mitogen-activated protein kinase pathway.
    Wang Z, Ge L, Wang M, Carr BI.
    J Cell Physiol; 2006 Jul 01; 208(1):133-40. PubMed ID: 16596619
    [Abstract] [Full Text] [Related]

  • 46. Omomyc, a potential Myc dominant negative, enhances Myc-induced apoptosis.
    Soucek L, Jucker R, Panacchia L, Ricordy R, Tatò F, Nasi S.
    Cancer Res; 2002 Jun 15; 62(12):3507-10. PubMed ID: 12067996
    [Abstract] [Full Text] [Related]

  • 47. Myc and Max proteins possess distinct transcriptional activities.
    Kretzner L, Blackwood EM, Eisenman RN.
    Nature; 1992 Oct 01; 359(6394):426-9. PubMed ID: 1406956
    [Abstract] [Full Text] [Related]

  • 48. Analysis of c-Myc and Max binding to the c-myc promoter: evidence that autosuppression occurs via an indirect mechanism.
    Buckle RS, Méchali M.
    Oncogene; 1995 Mar 16; 10(6):1249-55. PubMed ID: 7700652
    [Abstract] [Full Text] [Related]

  • 49. New structural determinants for c-Myc specific heterodimerization with Max and development of a novel homodimeric c-Myc b-HLH-LZ.
    Beaulieu ME, McDuff FO, Frappier V, Montagne M, Naud JF, Lavigne P.
    J Mol Recognit; 2012 Jul 16; 25(7):414-26. PubMed ID: 22733550
    [Abstract] [Full Text] [Related]

  • 50. c-Myc inhibits myogenic differentiation and myoD expression by a mechanism which can be dissociated from cell transformation.
    La Rocca SA, Crouch DH, Gillespie DA.
    Oncogene; 1994 Dec 16; 9(12):3499-508. PubMed ID: 7970710
    [Abstract] [Full Text] [Related]

  • 51. Myc-Max heterodimers activate a DEAD box gene and interact with multiple E box-related sites in vivo.
    Grandori C, Mac J, Siëbelt F, Ayer DE, Eisenman RN.
    EMBO J; 1996 Aug 15; 15(16):4344-57. PubMed ID: 8861962
    [Abstract] [Full Text] [Related]

  • 52. Induction of max by adrenomedullin and calcitonin gene-related peptide antagonizes endothelial apoptosis.
    Shichiri M, Kato H, Doi M, Marumo F, Hirata Y.
    Mol Endocrinol; 1999 Aug 15; 13(8):1353-63. PubMed ID: 10446908
    [Abstract] [Full Text] [Related]

  • 53. Sin3 corepressor function in Myc-induced transcription and transformation.
    Harper SE, Qiu Y, Sharp PA.
    Proc Natl Acad Sci U S A; 1996 Aug 06; 93(16):8536-40. PubMed ID: 8710905
    [Abstract] [Full Text] [Related]

  • 54. Induction of apoptosis by the c-Myc helix-loop-helix/leucine zipper domain in mouse 3T3-L1 fibroblasts.
    Kohlhuber F, Hermeking H, Graessmann A, Eick D.
    J Biol Chem; 1995 Dec 01; 270(48):28797-805. PubMed ID: 7499403
    [Abstract] [Full Text] [Related]

  • 55. TGF-beta1 regulates the expression of multiple max-interacting transcription factors in Balb/MK cells: implications for understanding the mechanism of action of TGF-beta1.
    Satterwhite DJ, White RL, Aakre ME, Moses HL.
    Pediatr Res; 2001 Jul 01; 50(1):67-75. PubMed ID: 11420421
    [Abstract] [Full Text] [Related]

  • 56. Protein complexes bearing myc-like antigenicity recognize two distinct DNA sequences.
    Negishi Y, Iguchi-Ariga SM, Ariga H.
    Oncogene; 1992 Mar 01; 7(3):543-8. PubMed ID: 1549367
    [Abstract] [Full Text] [Related]

  • 57. v-Myc, but not Max, possesses domains that function in both transcription activation and cellular transformation.
    Min S, Taparowsky EJ.
    Oncogene; 1992 Aug 01; 7(8):1531-40. PubMed ID: 1630816
    [Abstract] [Full Text] [Related]

  • 58. The N-myc oncoprotein is a transcriptional activator and associates with max and RB1 proteins.
    Wenzel A, Cziepluch C, Schürmann J, Schwab M.
    Prog Clin Biol Res; 1994 Aug 01; 385():59-66. PubMed ID: 7972238
    [No Abstract] [Full Text] [Related]

  • 59. The molecular role of Myc in growth and transformation: recent discoveries lead to new insights.
    Facchini LM, Penn LZ.
    FASEB J; 1998 Jun 01; 12(9):633-51. PubMed ID: 9619443
    [Abstract] [Full Text] [Related]

  • 60. Evidence for a cancer-specific switch at the CDK4 promoter with loss of control by both USF and c-Myc.
    Pawar SA, Szentirmay MN, Hermeking H, Sawadogo M.
    Oncogene; 2004 Aug 12; 23(36):6125-35. PubMed ID: 15208653
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 19.